best health software glp-1 alerts 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Drugs Revolutionize Weight Loss

Data show that up to two-thirds of patients with HFpEF have CAD or coronary microvascular dysfunction including ischaemia, which leads to disruption of LV diastolic and systolic function, development of fibrosis, increased myocardial stiffness and cardiac remodelling

For patients in this category, nutritionists will use more standard dietary counseling and weight loss approaches

Macrophage autophagy plays a protective role in advanced atherosclerosis

Otras opciones farmacolgicas incluyen fentermina/topiramato de liberacin prolongada (Qsymia) y naltrexona/bupropin (Contrave), aunque la evidencia especfica en poblacin post-baritrica es muy limitada